The Competitive Enterprise Institute released a new study finding that regulatory policy could inhibit the development of a generic market for biotech seeds once patents on those varieties expires.
Over the next decade, the patents on nearly two dozen of the most popular biotech crop traits will expire, and farmers in the U.S. and abroad are eager to get access to low-cost, generic versions of those seeds. But most biotech crop traits must be reapproved every three to five years, and the process requires applicants to have access to confidential business information held by the original product developers. This establishes a potentially impassable roadblock to the future of affordable, generic biotech products.
View the original article here: Generic biotech crops jeopardized by over-regulation – Western Farm Press